Lama Noureddine, MD
Nephrology · Iowa City, IANPI 1013176817
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Travere Therapeutics, Inc. accounts for 75.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $5,038 and has fallen 97.7% since, to $118 in 2025. Among nephrology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $423.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$5K
- Otsuka America Pharmaceutical, Inc.$1K
- Novartis$118
- GSK$36
Across 59 payments — averaging $11,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$130K
- Amgen$110K
- Vertex$82K
- Novartis$70K
- Sanofi$60K
- Genentech, Inc.$52K
- plus $147K from 5 others
What the payments were for
- Consulting fees$1,43521%
- Speaking & faculty fees$2,85042%
- Travel & lodging$1,61524%
- Food & beverage$81912%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 12 | $5,130 |
| Otsuka America Pharmaceutical, Inc. | 2 | $1,496 |
| Novartis | 1 | $118 |
| GSK | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$1,435
How this compares
$6,780 in reported general payments places this provider in the 90th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 71 | $67,355 |
| Everolimus | 12 | $34,509 |
| MounjaroTirzepatide | 30 | $30,145 |
| OzempicSemaglutide | 18 | $19,488 |
| RybelsusSemaglutide | 13 | $11,849 |
| Sevelamer Carbonate | 20 | $3,236 |
| Bumetanide | 18 | $611 |
| ClinisolParenteral Amino Acid 15% No.5 | 12 | $590 |
| Doxazosin Mesylate | 23 | $499 |
| Amlodipine Besylate | 70 | $440 |
| Lisinopril | 44 | $355 |
| Omeprazole | 19 | $346 |
| Allopurinol | 45 | $330 |
| Chlorthalidone | 17 | $323 |
| Atorvastatin Calcium | 34 | $297 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Iowa City
- Lawrence HunsickerIowa City$70K
- Benjamin GriffinIowa City$6K
- Mony FraerIowa City$5K
- Kantima PhisitkulIowa City$432
- Masaaki YamadaIowa City$271
- Waleed HassanIowa City$203
- Shahed AmmarIowa City$132
- Bahjat AzriehIowa City$119
- Timothy ChowIowa City$106
- Duha JweehanIowa City$91
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.